Nicox SA 

Nicox S.A. is an international ophthalmic pharmaceutical company, headquartered in Valbonne, France, and established in 1996. Its core mission is to develop innovative treatments aimed at preserving sight and enhancing overall eye health. The company's primary investigational compound, NCX 470, a cutting-edge nitric oxide-donating prostaglandin analog, is currently undergoing Phase 3 clinical trials. This candidate is designed to reduce elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Additionally, Nicox is advancing NCX 4251, a unique fluticasone formulation in Phase 2b clinical trials, specifically targeting severe flare-ups of blepharitis, alongside another promising candidate, NCX 1728, also under development. Beyond its pipeline, Nicox markets two key ophthalmic solutions: VYZULTA (latanoprostene bunod), prescribed for the management of open-angle glaucoma or ocular hypertension, and ZERVIATE (cetirizine), used to alleviate eye itching caused by allergic conjunctivitis.